Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.33 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | MMP9 | P14780 | 4/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7528125 | 0.87 | MMP1 (0.36) | MMP1MMP2MMP9ADAM17KMT2A | |
| SCHEMBL7528129 | 0.87 | MMP1 (0.36) | MMP1MMP2MMP9ADAM17KMT2A | |
| SCHEMBL7528133 | 0.87 | MMP1 (0.36) | MMP1MMP2MMP9ADAM17KMT2A | |
| SCHEMBL19852921 | 0.85 | GRIN2B (0.46) | GRIN2BGRIN2C | |
| Hydrochloric Acid SCHEMBL3530197 | 0.82 | MMP1 (0.36) | MMP1MMP2MMP9ADAM17 | |
| SCHEMBL18806165 | 0.82 | — | — | |
| SCHEMBL19852922 | 0.81 | LMNA (0.35) | LMNACA12CA1CA2CA3 | |
| SCHEMBL19852935 | 0.80 | LMNA (0.35) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13751286 | 0.78 | DPP4 (0.38) | — | |
| SCHEMBL13740583 | 0.78 | DPP4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655686-B2 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-7655686-B2 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| EP-1670803-B1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070265328-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265328-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | AUBERSON YVES | 2007-01-18 | — | — | US | disclosed |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | AUBERSON YVES | 2007-01-18 | — | — | US | disclosed |
| EP-1670803-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | Novartis AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670803-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | Novartis AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005035535-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005035535-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265328-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | MMP1 4570/4885MMP2 3136/4885MMP9 2810/4885 |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | MMP1 4570/4885MMP2 3136/4885MMP9 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.